A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis;Analiza stȩżenia biochemicznych markerów obrotu kostnego u chorych na miȩsaka kościopochodnego z korzystnym i niekorzystnym rokowaniem

Polski Merkuriusz Lekarski

Volumn 29, Issue 169, 2010, Pages 19-26

  Ambroszkiewicz, Jadwiga ^a   Gajewska, Joanna ^a   Klepacka, Teresa ^a   Chełchowska, Magdelena ^a   Laskowska Klita, Teresa ^a   Wozniak, Wojciech ^a  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Bone turnover markers; Children and adolescents; Osteosarcoma; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; ICTP PEPTIDE; OSTEOCALCIN; PEPTIDE FRAGMENT; PROCOLLAGEN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE TUMOR; CHILD; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; OSTEOSARCOMA; PRESCHOOL CHILD; PROGNOSIS;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; OSTEOCALCIN; OSTEOSARCOMA; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955955778     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ambroszkiewicz J., Gajewska J., Klepacka T. i wsp.: Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma. Pol. Merk. Lek., 2006, 21 (124), 330-334. (Pubitemid 44759453)
2. Bacci G., Picci P., Orlandi M. i wsp.: Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori, 1987, 73, 331-336.
3. Bath L.F., Crofton P.M., Evans A.E. i wsp.: Bone turnover and growth during and after chemotherapy in children with solid tumors. Pediatr. Res., 2004, 55 (2), 224-230.
4. Berrutti A., Piovesan A., Torta M. i wsp.: Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br. J. Cancer, 1996, 73, 1581-1587.
5. Body J.J., Dumon J.C., Gineyts J., Delmas P.D.: Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphomate therapy. Br. J. Cancer, 1997, 75, 408-412.
6. Burlina A., Rubin D., Secchiero S. i wsp.: Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin. Chim. Acta, 1994, 236, 151-158.
7. Chou A.J., Geller D S., Gorlick R.: Therapy for osteosarcoma; where do we go from here? Paediatr. Drugs, 2008, 10 (5), 315-327.
8. Coleman R.E.: Metastatic bone disease and the role of biochemical markers of bone metabolism in bening and malignant diseases. Cancer Tret. Rev., 2001, 27, 133-135.
9. Demers L.M.: Biochemical markers in the management of patients with metastatic bone disease. Clin. Chem., 1999, 45, 1131-1132.
10. Fanburg J.C., Rosenberg A.E., Weaver D.L. i wsp.: Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. Am. J. Clin. Pathol., 1997, 108, 464-473.
11. Ferrari S., Zolezzi C, Pratelli L. i wsp.: Urinary excretion of pyridinium cross-links and semm osteocalcin levels in patients with primary high-grade osteosarcoma. Calcif. Tissue Int., 2003, 73 (1), 1-4.
12. Fontana A., Delmas P.D.: Markers of bone turnover in bone metastases. Cancer, 2000, 88, 2952-2960.
13. Gajewska J., Ambroszkiewicz J., Klepacka T. i wsp.: Markers of bone formation and resorption in patients with mixed subtype osteosarcoma. Nowotwory, 2006, 56 (5), 525-530.
14. Jung K., Lein M., Stephan C. i wsp.: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer, 2004, 111, 783-791.
15. Koizumi M., Yamada Y, Takiguchi T. i wsp.: Bone metabolic markers in bone metastases. J. Cancer Res. Clin. Oncol., 1995, 121, 542-548.
16. Levine A.M., Triche T., Rosenberg S.A.: Osteosarcoma cells in tissue culture: Characterization and localization of alkaline phosphatase activity. Clin. Orthop. Rel. Res., 1980, 146, 259-268.
17. Liu P.P., Leung K.S., Kumta S.M. i wsp.: Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology, 1996, 53 (4), 275-280.
18. Osuna̧ D., de Alava E.: Molecular pathology of sarcomas. Rev. Recent Clin. Trials, 2009, 4, 12-26.
19. Sakamoto A., Iwamoto Y.: Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. Rev. Recent Clin. Trials, 2008, 3(3), 228-231.
20. Seregni E., Martinetti A., Ferrari L. i wsp.: Clinical utility of biochemical marker of bone remodeling in patients with bone metastases of solid tumors. Q. J. Nucl. Med., 2001, 45 (1), 7-17.
21. Tan M.L., Choong P.F., Dass C.R.: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol. Ther., 2009, 8 (2), 106-117.
22. Tang N., Song W.X., Luo J. i wsp.: Osteosarcoma development and stem cell differentiation. Clin. Orthop. Rel. Res., 2008, 466 (9), 2114-2130.
23. Wang J., Pei R, Tu C. i wsp.: Serum bone turnover markers in patients with primary bone tumors. Oncology, 2007, 72, 338-342.
24. Wasilewski-Masker K., Kastle S.C., Hudson M.M. i wsp.: Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics, 2008, 121 (3), 705-713.
25. Woźniak W.: Miȩsak kościopochodny u dzieci. W: Guzy kości u dzieci. Diagnostyka i leczenie. Stoba C, Czauderna P. (red.) Folium, Lublin, 1997, 123-128.
26. Zhiping Y, Yanqing H., Guangzhi S. i wsp.: Measurement of bone alkaline phosphatase and relative study with osteosarcoma. Front. Med. China, 2007, 1 (1), 54-57.